Physician profile
Benjamin W Cole
NPI 1215399670
$3,017.77
in general payments reported to CMS, 2019-2025
26 companies · $540 in 2025
The $540 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.66 · 2020: $156 · 2021: $422 · 2022: $575 · 2023: $577 · 2024: $648 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $459.95 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $356.31 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $335.66 | 2020-2025 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $243.13 | 2019-2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $212.10 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $199.06 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi Pasteur INC. | $179.55 | 2021-2024 | |
| Pfizer INC. | $145.44 | 2020-2025 | |
| Cranial Technologies, INC | $109.79 | 2019-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $103.35 | 2023-2025 | |
| Kaleo, INC. | $97.95 | 2020-2024 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $91.96 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $87.65 | 2021-2022 | |
| Tris Pharma INC | $79.64 | 2021-2024 | Dyanavel Xr |
| Genentech USA, INC. | $53.65 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $50.52 | 2019-2025 | Relexxii |
| Ars Pharmaceuticals Operations, INC. | $44.65 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $24.77 | 2025 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $23.63 | 2024 | Flumist Quadrivalent |
| Acadia Pharmaceuticals INC | $22.41 | 2025 | Daybue |
| Cognoa, INC. | $18.75 | 2022 | |
| Seqirus USA INC | $18.36 | 2025 | Flucelvax |
| Exeltis, USA INC. | $16.66 | 2023 | Slynd |
| Kowa Pharmaceuticals America, INC. | $16.50 | 2025 | Zoryve |
| Alexion Pharmaceuticals, INC. | $13.32 | 2023 | Strensiq |
| Teva Pharmaceuticals USA, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.